Selected excepts from ADXS IR... A significant number of collaborations, regulatory endorsements and shots on goal over 11 years to arrive at our current 2 or 3 product standing with AXAL(?), NEO and HOT. Many of the earlier initiatives appear to have just evaporated into the ether as they haven’t been referenced by ADXS in years or I assume exist in some form of suspended animation. As a small biotech with limited funding - hindsight might suggest ADXS was overly ambitious and spread themselves very thin with too many non or under funded initiatives they’ve now suspended.
Very unfortunate as many of the products they’ve been forced to abandon appear to have important medical potential. I hope they’ve chosen the remaining product portfolio wisely. The companies complete IR history back to 2007 is painful to review. Its interwoven with early scientific promise as well as managerial greed and numerous operational missteps and over-reach. G.B.
Advaxis Announces Dosing of First Patient with ADXS-NEO, an Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens
Jun 11, 2018
Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union
Feb 13, 2018
Advaxis and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate ADXS-DUAL and Opdivo (nivolumab) in Metastatic Cervical Cancer
May 30, 2017
Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy
Feb 27, 2017
Advaxis’ Axalimogene Filolisbac to be Developed and Commercialized in Latin America With Stendhal
Feb 3, 2016
Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration
Aug 2, 2016
Advaxis’ AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients
Jul 21, 2016
European Medicines Agency Committee Classifies Advaxis’ Axalimogene Filolisbac as an Advanced-Therapy Medicinal Product
Jul 18, 2016
FDA Grants Special Protocol Assessment to Advaxis’ Phase 3 Study of AXAL in Patients with Cervical Cancer
Jul 6, 2016
FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma
Apr 28, 2016
Advaxis Receives Orphan Drug Designation in the European Union for Axalimogene Filolisbac for the Treatment of Anal Cancer
Dec 14, 2015
Advaxis Receives Orphan Drug Designation in the European Union for ADXS-HER2 for the Treatment of Osteosarcoma
Dec 1, 2015
FDA Awards Grant for Phase 2 Study of Axalimogene Filolisbac (ADXS-HPV) in HPV-Associated Head and Neck Cancer
Sep 14, 2015
Advaxis Announces Licensing Agreement With Knight Therapeutics and Raises $25 Million Through Direct Investments From Knight and Sectoral Asset Management
Aug 26, 2015
Advaxis Announces FDA Clearance of Investigational New Drug Application for Phase 2 Study of ADXS-HPV and Incyte's epacadostat for the Treatment of HPV-Associated Early Stage Cervical Cancer
Jun 1, 2015
Advaxis and Sorrento Form Collaboration to Evaluate Combinations of Advaxis's Lm-LLO Immunotherapy Technology and Sorrento's Immunomodulatory Antibodies
May 19, 2015
Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-PSA in Combination With Merck's KEYTRUDA(R) (pembrolizumab) for Prostate Cancer
Dec 8, 2014
Advaxis Submits Investigational New Drug Application for Phase 1/2 Study of ADXS-HPV and MedImmune's MEDI4736 for the Treatment of HPV-Associated Cervical and Head & Neck Cancer
Nov 12, 2014
Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer
Aug 25, 2014
Advaxis to Ring The NASDAQ Stock Market Closing Bell
Mar 26, 2014
Advaxis and UC San Francisco to Evaluate Cancer Immunotherapy Constructs in Prostate Cancer
Mar 17, 2014
Advaxis Signs Exclusive Licensing Agreement for Development and Commercialization of ADXS-HPV in Asia
Dec 9, 2013
Advaxis Awarded Best Therapeutic Vaccine
Apr 12, 2012
Advaxis Announces Collaboration with Wistar Institute
Apr 14, 2011
Advaxis India Cervix Cancer Trial Begins Dosing
Nov 24, 2010
Advaxis Enters into Collaboration with the University of British Columbia
Nov 8, 2010
India Approves Advaxis Trial in Cervix Cancer
Sep 22, 2010
Advaxis Signs Agreement with Cobra For Manufacture of Lovaxin C Vaccine
Oct 18, 2007
